[Neonatal cystic fibrosis screening]
Paz Valinas L, Garcia Vega F-J
Record ID 32005000458
Spanish
Authors' objectives:
Based on available scientific evidence, the aim of this review was to assess the efficacy/effectiveness of neonatal cystic fibrosis (CF) screening in reducing associated mortality and/or morbidity.
Authors' results and conclusions:
Three systematic reviews and a number of subsequently published studies were located. The studies that produced the highest-quality scientific evidence were randomised clinical control trials conducted in the USA and United Kingdom. Outcomes indicated a certain benefit at a pulmonary and nutritional level as a result of early treatment, following detection of the disease through screening. This benefit was only observed in the short term, however, and the studies involved were not free of methodological biases. Insofar as a reduction in CF mortality was concerned, neonatal screening was not observed to have a direct effect on this outcome variable.
Authors' recommendations:
Taking the screening principles and quality of the scientific evidence of the above studies into account, we have concluded that neonatal cystic fibrosis screening fails to fulfil all the necessary criteria required for generalised implementation. Although there seems to be some evidence of certain beneficial effects in some parameters, this is nonetheless inadequate to demonstrate the screening programme's efficacy/effectiveness.
Authors' methods:
Systematic review
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
https://extranet.sergas.es/catpb/Docs/cas/Publicaciones/Docs/avalia-t/PDF-1129-es.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Humans
- Cystic Fibrosis
- Infant, Newborn
- Neonatal Screening
- Program Evaluation
Contact
Organisation Name:
Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
Contact Address:
Conselleria de Sanidade, Xunta de Galicia, San Lazaro s/n 15781 Santiago de Compostela, Spain. Tel: 34 981 541831; Fax: 34 981 542854;
Contact Name:
avalia-t@sergas.es
Contact Email:
avalia-t@sergas.es
Copyright:
<p>Galician Agency for Health Technology Assessment (AVALIA-T)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.